ReviewNature reviews. Neurology2026
Modelling brain tumours with organoids: towards precision medicine in neuro-oncology.
Review in Nature reviews. Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Immunotherapy for Diffuse Midline Glioma: From Preclinical Modeling to Clinical Translation.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precision medicine in neuro-oncology hinges on our ability to decode the molecular and functional complexity of brain tumours. These tumours are highly heterogeneous and dynamic ecosystems that remain challenging to replicate with traditional experimental models. Organoids have emerged as next-generation tools for capturing the diversity of brain tumours in a clinically relevant context. Here, we review advances in applying organoids as tumour avatars to foster precision medicine. We assess current methodologies for generating organoids from various brain tumour types and illustrate how these models have enhanced mechanistic insight into tumour initiation, progression and resistance to treatment. Furthermore, we explore their translational potential in functional drug screening and treatment stratification, offering a powerful preclinical and co-clinical platform with which to personalize neuro-oncology.
Indexed as
Identifiers
41807744What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.